☆ 4.7 Meeting Abstract

A phase 1 study of PF-06647020, an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients with advanced solid tumors including platinum resistant ovarian cancer (OVCA)

ANNALS OF ONCOLOGY (2016)

Journal

ANNALS OF ONCOLOGY

Volume 27, Issue -, Pages -

Publisher

OXFORD UNIV PRESS

DOI: 10.1093/annonc/mdw435.29

Keywords

-

Categories

Oncology

Funding

Pfizer

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Immunology

Therapeutic strategies targeting folate receptor a for ovarian cancer

Jia Mai, Limei Wu, Ling Yang, Ting Sun, Xiaojuan Liu, Rutie Yin, Yongmei Jiang, Jinke Li, Qintong Li

Summary: Epithelial ovarian cancer is a deadly gynecological cancer, and targeting the folate receptor alpha has shown promise in its treatment. Various modalities, including antibody-drug conjugates, monoclonal antibodies, and small molecules, have been explored to exploit this target for effective therapy.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Article Oncology

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer

Pasi A. Janne, Christina Baik, Wu-Chou Su, Melissa L. Johnson, Hidetoshi Hayashi, Makoto Nishio, Dong-Wan Kim, Marianna Koczywas, Kathryn A. Gold, Conor E. Steuer, Haruyasu Murakami, James Chih-Hsin Yang, Sang-We Kim, Michele Vigliotti, Rong Shi, Zhenhao Qi, Yang Qiu, Lihui Zhao, David Sternberg, Channing Yu, Helena A. Yu

Summary: HER3-DXd shows clinical activity in EGFR TKI-resistant lung cancer, regardless of resistance mechanisms, providing a new approach to treat drug-resistant cancers.

CANCER DISCOVERY (2022)

Add to Collection

Article Oncology

An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer

Joyce Liu, Howard Burris, Judy S. Wang, Lisa Barroilhet, Martin Gutierrez, Yulei Wang, Anjali Vaze, Renee Commerford, Stephanie Royer-Joo, Voleak Choeurng, Eric Humke, Kathleen Moore

Summary: In this trial, DMUC4064A showed acceptable safety and promising efficacy in patients with platinum-resistant OC, with 25% of patients experiencing confirmed partial responses, 40% experiencing ocular toxicities, and a clinical benefit rate of 42%.

GYNECOLOGIC ONCOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now?

Aimee Rendell, Isobel Thomas-Bland, Lee McCuish, Christopher Taylor, Mudra Binju, Yu Yu

Summary: Ovarian cancer is a deadly gynecological malignancy. Targeting receptor tyrosine kinases has shown potential for treating ovarian cancer, but monotherapeutic agents have not been effective. Combination therapy with tyrosine kinase inhibitors and monoclonal antibodies appears more promising, especially in platinum-sensitive tumors. Immunotherapeutic vaccines have also shown some efficacy but require further development.

BIOMEDICINES (2022)

Add to Collection

Article Oncology

Research trends and prospects on brain metastasis from breast cancer: A bibliometric analysis

Si-qi Wu, Yan Liu, Jie Zhou, Yan-ting You, Xing-hong Zhou, Li-qian Chen, Hiu Yee Kwan, Xiao-shan Zhao, Yi-fen Wu, Yan-yan Liu

Summary: This article provides an updated summary on the development, hotspots, and research trends of brain metastasis from breast cancer using bibliometric analysis. The results demonstrate that high-income countries have made more contributions to this field, while developing countries like China have shown rapid development. The success of novel therapies in recent years may lead to a new era of treatment for breast cancer with brain metastasis in the future.

FRONTIERS IN ONCOLOGY (2023)

Add to Collection

Article Oncology

Mirvetuximab soravtansine for platinum-resistant epithelial ovarian cancer

Rebecca L. Porter, Ursula A. Matulonis

Summary: Mirvetuximab soravtansine is an antibody drug conjugate used for the treatment of high grade serous ovarian cancer. It has shown high efficacy and favorable safety profile by targeting folate receptor alpha and releasing cytotoxic agents. This research holds great importance for the development of mirvetuximab combinations in platinum sensitive and newly diagnosed ovarian cancer patients.

EXPERT REVIEW OF ANTICANCER THERAPY (2023)

Add to Collection

Review Oncology

Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

Eduardo Gonzalez-Ochoa, Ana C. Veneziani, Amit M. Oza

Summary: Ovarian cancer ranks second globally in the mortality rate of gynecologic malignancies. Managing platinum-resistant disease is challenging and the outcomes of standard chemotherapy are unsatisfactory. Efforts have been made to understand drug resistance and develop strategies to overcome treatment failure. Mirvetuximab soravtansine, an antibody drug conjugate (ADC), has shown promising clinical activity in patients with platinum-resistant ovarian cancer by combining tumor-specific antigen targeting ability with cytotoxic chemotherapy effects. This review summarizes the current evidence of mirvetuximab soravtansine in platinum-resistant ovarian cancer, focusing on its clinical activity, toxicity, and future directions.

CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2023)

Add to Collection

Article Oncology

Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR?)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

Lucy Gilbert, Ana Oaknin, Ursula A. Matulonis, Gina M. Mantia-Smaldone, Peter C. Lim, Cesar M. Castro, Diane Provencher, Sanaz Memarzadeh, Michael Method, Jiuzhou Wang, Kathleen N. Moore, David M. O'Malley

Summary: The combination of mirvetuximab soravtansine and bevacizumab demonstrated antitumor activity and safety in patients with platinum-resistant ovarian cancer. The treatment achieved high objective response rate (44%) and prolonged duration of response (median 9.7 months). The study suggests that mirvetuximab soravtansine could be a potential combination partner for bevacizumab in this patient population.

GYNECOLOGIC ONCOLOGY (2023)

Add to Collection

Review Oncology

Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management

Joaquim Bellmunt, Begona P. Valderrama, Javier Puente, Enrique Grande, M. Victoria Bolos, Nuria Lainez, Sergio Vazquez, Pablo Maroto, Miguel Angel Climent, Xavier Garcia del Muro, Jose Angel Arranz, Ignacio Duran

Summary: Management of first-line advanced urothelial carcinoma (UC) has traditionally involved platinum-based chemotherapy followed by observation. Recent therapeutic developments, including first-line maintenance therapy and the incorporation of new drug classes, have improved outcomes for this patient population.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2022)

Add to Collection

Article Oncology

A Phase I Trial of CT900, a Novel a-Folate Receptor- Mediated Thymidylate Synthase Inhibitor, in Patients with Solid Tumors with Expansion Cohorts in Patients with High-Grade Serous Ovarian Cancer

Susana Banerjee, Vasiliki Michalarea, Joo Ern Ang, Alvaro Ingles Garces, Andrea Biondo, Ionut-Gabriel Funingana, Martin Little, Ruth Ruddle, Florence Raynaud, Ruth Riisnaes, Bora Gurel, Sue Chua, Nina Tunariu, Joanna C. Porter, Toby Prout, Mona Parmar, Anna Zachariou, Alison Turner, Ben Jenkins, Stuart McIntosh, Ed Ainscow, Anna Minchom, Juanita Lopez, Johann de Bono, Robert Jones, Emma Hall, Natalie Cook, Bristi Basu, Udai Banerji

Summary: CT900 is a novel small molecule inhibitor that selectively targets α-folate receptor overexpressing tumors. A dose of 12 mg/m2 every 2 weeks was found to be well-tolerated and showed clinical benefit in patients with high/medium α-FR expression.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Review Pharmacology & Pharmacy

Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options

Vikas Garg, Amit M. Oza

Summary: Ovarian cancer is the leading cause of gynecological cancer death. Although there have been improvements in treatment, half of the patients still die within 5 years. The resistance mechanisms of PARP inhibitors have been extensively studied, and strategies to overcome resistance exist.

DRUGS (2023)

Add to Collection

Review Pharmacology & Pharmacy

Advances in the treatment of platinum resistant epithelial ovarian cancer: an update on standard and experimental therapies

Shuk on Annie Leung, Panagiotis A. Konstantinopoulos

Summary: PROC is defined as disease recurrence within 6 months of completing platinum-based chemotherapy, generally associated with poor outcomes and low response rates. Recent developments in therapeutics based on biomarkers and a more nuanced understanding of DNA repair and immunologic pathways have led to novel treatment options, such as PARP inhibitors, cell cycle checkpoint inhibitors, and immune checkpoint inhibitors.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)

Add to Collection

Article Oncology

ARTISTRY-7: Phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer

Thomas J. Herzog, John L. Hays, Joyce N. Barlin, Joseph Buscema, Noelle G. Cloven, Lynn R. Kong, Nidhi Kumar Tyagi, Grainger S. Lanneau, Beverly J. Long, Robert L. Marsh, Shelly M. Seward, David C. Starks, Stephen Welch, Kathleen N. Moore, Panagiotis A. Konstantinopoulos, Lucy Gilbert, Bradley J. Monk, David M. O'Malley, Xiwei Chen, Rita Dalal, Robert L. Coleman, Jalid Sehouli

Summary: Nemvaleukin alfa is a novel cytokine designed to treat platinum-resistant/refractory ovarian cancer by selectively activating cytotoxic CD8(+) T cells and natural killer cells. In the global clinical trial ARTISTRY-7, the efficacy and safety of the combination of nemvaleukin and pembrolizumab are being evaluated in previously treated platinum-resistant ovarian cancer patients.

FUTURE ONCOLOGY (2023)

Add to Collection

Review Oncology

A narrative review of antibody-drug conjugates in EGFR-mutated non-small cell lung cancer

Robert Hsu, David J. Benjamin

Summary: In the past 15 years, treatment for NSCLC has changed significantly due to the discovery of mutations and the development of new targeted therapies and immune checkpoint inhibitors. EGFR mutation was the first to have an FDA-approved drug for NSCLC. However, resistance to osimertinib is a known issue. ADCs offer a new approach by bypassing intracellular resistance mechanisms. This article summarizes the mechanism and investigational use of ADCs for EGFR-mutated NSCLC.

FRONTIERS IN ONCOLOGY (2023)

Add to Collection

Review Oncology

Identification and prioritization of tumour-associated antigens for immunotherapeutic and diagnostic capacity in epithelial ovarian cancer: a systematic literature review

Lucy Wiseman, Noemi Cinti, Barbara-ann Guinn

Summary: Profiling of tumour-associated antigens (TAAs) is important for the diagnosis and treatment of epithelial ovarian cancer (EOC), with CA-125 being the most promising target. This study identified potential TAAs through systematic literature search and evaluated their diagnostic and treatment potential.

CARCINOGENESIS (2022)

Add to Collection

Article Oncology

GITR Antibodies in Cancer: Not Ready for Prime Time

Tatiana Hernandez-Guerrero, Victor Moreno

Summary: Glucocorticoid-induced TNF receptor (TNFR)-related protein (GITR) agonistic antibodies enhance the antitumor response by reducing the effect of Foxp3+ T-regulatory cells. However, the novel GITR agonist TRX-518 has shown limited clinical activity in patients with advanced solid tumors.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Oncology

Final Safety and Health-Related Quality of LIfe Results of the Phase 2/3 Act.In.Sarc Study With Preoperative NBTXR3 Plus Radiation Therapy Versus Radiation Therapy in Locally Advanced Soft-Tissue Sarcoma

Sylvie Bonvalot, Piotr L. Rutkowski, Juliette Thariat, Sebastien Carrere, Anne Ducassou, Marie-Pierre Sunyach, Peter Agoston, Angela M. Hong, Augustin Mervoyer, Marco Rastrelli, Victor Moreno, Rubi K. Li, Beatrice J. Tiangco, Antonio Casado Herra, Alessandro Gronchi, Teresa Sy-Ortin, Peter Hohenberger, Thierry de Baere, Axel Le Cesne, Sylvie Helfre, Esma Saada-Bouzid, Rodica M. Anghel, Guy Kantor, Angel Montero, Herbert H. Loong, Ramona Verges, Gabriel Kacso, Lyn Austen, Vincent F. Servois, Eva Wardelmann, Mikaela Dimitriu, Patricia Said, Alexander J. Lazar, Judith V. M. G. Bovee, Cecile Le Pechoux, Zsusanna Papai

Summary: The study Act.In.Sarc demonstrated that NBTXR3, a first-in-class radioenhancer, activated by preoperative radiation therapy, can improve the pathologic complete response rate and achieve R0 resections in patients with locally advanced soft tissue sarcoma. The study also showed that NBTXR3 does not negatively impact health-related quality of life and safety.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)

Add to Collection

Article Oncology

A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer

Robert Jones, Ruth Plummer, Victor Moreno, Louise Carter, Desamparados Roda, Elena Garralda, Rebecca Kristeleit, Debashis Sarker, Tobias Arkenau, Patricia Roxburgh, Harriet S. Walter, Sarah Blagden, Alan Anthoney, Barbara J. Klencke, Mark M. Kowalski, Udai Banerji

Summary: The purpose of this study was to assess the safety, recommended dose, pharmacokinetic profile, and clinical activity of the novel checkpoint kinase 1 (Chk1) inhibitor SRA737 in combination with gemcitabine in patients with advanced solid tumors. The results showed that the combination of SRA737 and low-dose gemcitabine was well tolerated and demonstrated tumor responses in anogenital cancer and other solid tumors.

CLINICAL CANCER RESEARCH (2023)

Add to Collection

Article Oncology

A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors

Victor Moreno, Ruth Perets, Tamar Peretz-Yablonski, Nele Fourneau, Suzette Girgis, Yue Guo, Peter Hellemans, Raluca Verona, Natalia Pendas, Qi Xia, Ravit Geva, Emiliano Calvo

Summary: Mitazalimab, a human monoclonal antibody targeting CD40, was evaluated in this study for anti-tumor immunotherapy. The results demonstrated its manageable safety profile and pharmacokinetic/pharmacodynamic properties, suggesting its potential as a treatment option for solid malignancies.

INVESTIGATIONAL NEW DRUGS (2023)

Add to Collection

Article Oncology

Trotabresib, an oral potent bromodomain and extraterminal inhibitor, in patients with high-grade gliomas: A phase I, window-of-opportunity study

Victor Moreno, Juan Manuel Sepulveda, David A. Reardon, Angel Perez-Nunez, Pedro Gonzalez Leon, Bishoy Hanna, Ellen Filvaroff, Ida Aronchik, Henry Chang, Barbara Amoroso, Marlene Zuraek, Tania Sanchez-Perez, Cristina Mendez, Daniel Stephens, Zariana Nikolova, Michael A. Vogelbaum

Summary: This study investigates the pharmacokinetics, pharmacodynamics, and CNS penetration of the BET inhibitor trotabresib in patients with recurrent high-grade gliomas. The results show that trotabresib penetrates the blood-brain-tumor barrier and demonstrates target engagement in resected tumor tissue. The pharmacokinetics, pharmacodynamics, and safety of trotabresib in these patients are comparable to previous results in patients with advanced solid tumors.

NEURO-ONCOLOGY (2023)

Add to Collection

Article Oncology

A Phase 1/2 study of the PD-L1 inhibitor, BGB-A333, alone and in combination with the PD-1 inhibitor, tislelizumab, in patients with advanced solid tumours

Jayesh Desai, Peter Fong, Victor Moreno, Sophia Frentzas, Tarek Meniawy, Ben Markman, Mark Voskoboynik, Tahmina Rahman, Nageshwar Budha, John Wu, Jin Marlow, Silu Yang, Emiliano Calvo, Juan Martin-Liberal

Summary: This study investigated the safety and anti-tumor activity of BGB-A333, a PD-L1 inhibitor, alone and in combination with tislelizumab in patients with advanced solid tumors. The results showed that BGB-A333 in combination with tislelizumab demonstrated promising anti-tumor activity.

BRITISH JOURNAL OF CANCER (2023)

Add to Collection

Article Cell Biology

A first-in-human study of the fibroblast activation protein-targeted, 4-1BB agonist RO7122290 in patients with advanced solid tumors

Ignacio Melero, Tamara Tanos, Mariana Bustamante, Miguel F. Sanmamed, Emiliano Calvo, Irene Moreno, Victor Moreno, Tatiana Hernandez, Maria Martinez Garcia, Alejo Rodriguez-Vida, Josep Tabernero, Analia Azaro, Mariano Ponz-Sarvise, Iben Spanggaard, Kristoffer Rohrberg, Ernesto Guarin, Eveline Nuesch, Iakov I. Davydov, Chiahuey Ooi, Jose Duarte, Evelyne Chesne, Christine McIntyre, Maurizio Ceppi, Marta Canamero, Oliver Krieter

Summary: This first-in-human study evaluated the effectiveness of RO7122290, a bispecific fusion protein, in stimulating T cells for improved tumor cell killing in FAP-expressing tumors. The study involved administering escalating doses of RO7122290, both as a single agent and in combination with atezolizumab, to patients with advanced or metastatic solid tumors. The results showed promising pharmacokinetics and treatment-induced changes in peripheral and tissue biomarkers, supporting further evaluation of RO7122290 in combination with immune-oncology agents for solid tumor treatment.

SCIENCE TRANSLATIONAL MEDICINE (2023)

Add to Collection

Article Multidisciplinary Sciences

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers

James J. Harding, Sarina A. Piha-Paul, Ronak H. H. Shah, Jessica J. Murphy, James M. Cleary, Geoffrey I. Shapiro, David I. Quinn, Irene Brana, Victor Moreno, Mitesh Borad, Sherene Loi, Iben Spanggaard, Haeseong Park, James M. Ford, Monica Arnedos, Salomon M. Stemmer, Christelle de la Fouchardiere, Christos Fountzilas, Jie Zhang, Daniel DiPrimeo, Casey Savin, S. Duygu Selcuklu, Michael F. Berger, Lisa D. Eli, Funda Meric-Bernstam, Komal Jhaveri, David B. Solit, Ghassan K. Abou-Alfa

Summary: In patients with biliary tract cancer, HER2 alterations correlate with poor prognosis. A phase II clinical trial showed that the tyrosine kinase inhibitor neratinib has some efficacy in treating advanced biliary tract cancers with HER2-mutation positive. The objective response rate to neratinib was 16% (95% CI 4.5-36.1%).

NATURE COMMUNICATIONS (2023)

Add to Collection

Article Multidisciplinary Sciences

BET inhibitor trotabresib in heavily pretreated patients with solid tumors and diffuse large B-cell lymphomas

Victor Moreno, Maria Vieito, Juan Manuel Sepulveda, Vladimir Galvao, Tatiana Hernandez-Guerrero, Bernard Doger, Omar Saavedra, Carmelo Carlo-Stella, Jean-Marie Michot, Antoine Italiano, Massimo Magagnoli, Cecilia Carpio, Antonio Pinto, Rafael Sarmiento, Barbara Amoroso, Ida Aronchik, Ellen Filvaroff, Bishoy Hanna, Xin Wei, Zariana Nikolova, Irene Brana

Summary: Bromodomain and extraterminal proteins (BET) are important in gene expression regulation and may play a role in cancer. In this study, the efficacy and safety of a BET inhibitor called trotabresib were evaluated in patients with advanced solid tumors and relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The results showed that trotabresib monotherapy had antitumor activity, with a response rate of 13.0% in DLBCL patients and a response rate of 0.0% in advanced solid tumor patients. These findings support further investigation of trotabresib in combination with other anticancer agents.

NATURE COMMUNICATIONS (2023)

Add to Collection

Article Oncology

Genomic Mapping of Epidermal Growth Factor Receptor and Mesenchymal-Epithelial Transition-Up-Regulated Tumors Identifies Novel Therapeutic Opportunities

Lucia Paniagua-Herranz, Bernard Doger, Cristina Diaz-Tejeiro, Adrian Sanvicente, Cristina Nieto-Jimenez, Victor Moreno, Pedro Perez Segura, Balazs Gyorffy, Emiliano Calvo, Alberto Ocana

Summary: This study explored the high expression of EGFR and MET in prostate adenocarcinoma and pancreatic adenocarcinoma, and found that it was related to high expression of PD-L1, suggesting the potential for future combination therapy using bi-specific EGFR/MET antibodies and anti-PD(L)1 inhibitors.

CANCERS (2023)

Add to Collection

Article Oncology

Phase 1 Study of JNJ-64619178, a Protein Arginine Methyltransferase 5 Inhibitor, in Advanced Solid Tumors

Maria Vieito, Victor Moreno, Anna Spreafico, Irene Brana, Judy S. Wang, Meir Preis, Tatiana Hernandez, Sofia Genta, Aaron R. Hansen, Bernard Doger, Vladimir Galvao, Laurie Lenox, Regina J. Brown, Anna Kalota, Jaydeep Mehta, Friederike Pastore, Bharvin Patel, Pankaj Mistry, Junchen Gu, Josh Lauring, Manish R. Patel

Summary: In this study, a selective and potent PRMT5 inhibitor was evaluated for its safety and efficacy in advanced malignant solid tumors or non-Hodgkin lymphoma patients. The results showed that the inhibitor demonstrated good anti-tumor activity and manageable toxicity in treating adenoid cystic carcinoma and other tumor types. Two recommended doses were determined based on the study findings. The clinical benefits of the inhibitor in other tumor types were limited.

CLINICAL CANCER RESEARCH (2023)

Add to Collection

Article Oncology

Safety and Tolerability of a Novel Anti-HER2 Antibody-Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study

Funda Meric-Bernstam, Emiliano Calvo, Keun Seok Lee, Victor Moreno, Yeon Hee Park, Sun Young Rha, Pavani Chalasani, Wei Zhong, Li Zhou, Steven Pirie-Shepherd, Abraham C. F. Leung, Giuseppe Curigliano

Summary: This study evaluated the safety and antitumor activity of PF-06804103 in patients with advanced/unresectable or metastatic breast and gastric cancers. The results showed that PF-06804103 demonstrated antitumor activity, but adverse events led to a high rate of treatment discontinuation.

MOLECULAR CANCER THERAPEUTICS (2023)

Add to Collection

Article Oncology

Patient Characteristics Associated with Growth of Patient-Derived Tumor Implants in Mice (Patient-Derived Xenografts)

Tatiana Hernandez Guerrero, Natalia Banos, Laura del Puerto Nevado, Ignacio Mahillo-Fernandez, Bernard Doger De-Speville, Emiliano Calvo, Michael Wick, Jesus Garcia-Foncillas, Victor Moreno

Summary: This study aimed to determine the factors that may predict better engraftment rates in patient-derived xenografts (PDXs). The use of systemic antibiotics and steroids by patients prior to sampling were found to impact the likelihood of success in PDX development. Furthermore, certain clinical, pathological, and molecular factors such as lactate dehydrogenase levels, grade of differentiation, Ki67 levels, presence of lymphovascular invasion, and mismatch repair status were correlated with engraftment success in PDXs.

CANCERS (2023)

Add to Collection

Meeting Abstract Oncology

Predictive factors for successful growth of patient derived xenografts (PDX).

Tatiana Hernandez-Guerrero, Bernard Doger, Jesus Garcia-Foncillas, Michael Jude Wick, Victor Moreno

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

Lurbinectedin in patients with pretreated BRCA1/2-associated metastatic breast cancer: Results from a phase II basket study.

Valentina Boni, Barbara Pistilli, Irene Brana, Geoffrey Shapiro, Jose Manuel Manuel Trigo Perez, Victor Moreno, Daniel E. Castellano, Cristian Marcelo Fernandez, Carmen Maria Kahatt, Vicente Alfaro, Mariano Siguero, Ali Hassan Zeaiter, Federico Longo, Khalil Zaman, Antonio Anton Torres, Alfredo Paredes Lario, Gerardo Huidobro Vence, Vivek Subbiah

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.